AKBA Stock Performance, Insider Transaction and News

AKBA - Akebia Therapeutics, Inc.

Market Cap	321.66M	P/E	-	EPS this Y	7.10%	Ern Qtrly Grth	-
Income	-43.03M	Forward P/E	-10.81	EPS next Y	-26.90%	50D Avg Chg	45.00%
Sales	187.22M	PEG	-	EPS past 5Y	-	200D Avg Chg	127.00%
Dividend	N/A	Price/Book	N/A	EPS next 5Y	-	52W High Chg	-6.00%
Recommedations	1.70	Quick Ratio	1.03	Shares Outstanding	209.60M	52W Low Chg	618.00%
Insider Own	2.14%	ROA	-8.37%	Shares Float	203.83M	Beta	0.77
Inst Own	27.06%	ROE	-	Shares Shorted/Prior	18.66M/12.30M	Price	1.73
Gross Margin	83.41%	Profit Margin	-22.99%	Avg. Volume	2,142,154	Target Price	5.00
Oper. Margin	-43.82%	Earnings Date	Aug 23	Volume	2,121,982	Change	-5.98%

Healthcare | Biotechnology | United States

About Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Akebia Therapeutics, Inc. News

07/11/24	Akebia Regains Full Rights to Sell Vafseo Tablets in US After Ending Licensing Deal With CSL Vifor
07/11/24	Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets
07/01/24	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:18 AM	Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
06/24/24	Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
06/21/24	Further weakness as Akebia Therapeutics (NASDAQ:AKBA) drops 16% this week, taking five-year losses to 80%
05/23/24	Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference
05/14/24	Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
05/11/24	Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
05/10/24	Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
05/10/24	Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
05/10/24	Akebia Therapeutics First Quarter 2024 Earnings: Misses Expectations
05/09/24	Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
05/09/24	Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
05/02/24	Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
04/28/24	When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
03/28/24	FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
03/28/24	Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
07:26 PM	Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
03/17/24	Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33

AKBA Chatroom

sgluckey Posted - 4 hours ago

$AKBA this seems like it was the only red day in a month

fresh10 Posted - 8 hours ago

$AKBA anybody else tired of seeing 1.44-1.46?

asavasir Posted - 8 hours ago

$AKBA this year is that year.

LongStockSniper Posted - 8 hours ago

$AKBA Consolidation then push up expected for next week. The stock looks good to keep climbing.

_BOOMGOTTEM Posted - 8 hours ago

$AKBA

Justinkorr Posted - 9 hours ago

$AKBA Friday... Even so, today's closing price is disappointing. It seems to have closed at a bad price.

Jeko44 Posted - 9 hours ago

$AKBA ok, real question, though not directly related to Akebia. I just trust this board more than others… I turned on stock lending in Webull this week to check it out and see what happens. For one of my holdings, the number of shares on loan is almost 20% more than the shares I own. How does that work?

Aamadeus Posted - 10 hours ago

$AKBA those morons. Tireless suckers

Smolik Posted - 10 hours ago

$AKBA Like I said. these cucks are just too predictable.

Luchbox Posted - 10 hours ago

$AKBA Up 9% in a week. I will that that.

jd_76 Posted - 11 hours ago

$AKBA well that was uneventful and now we are earnings coming up hope they’re promising

DrKennethNoisewater Posted - 11 hours ago

$AKBA this is an A+ setup based on my criteria. No guarantees ever in the market, but probability of a move up is high. Even if I had no knowledge of the company, it would be a buy for me here. Good luck next week everyone and hopefully earnings does not ruin this beauty of a chart that is shaping up.

Jeko44 Posted - 11 hours ago

$AKBA I think I discovered why we're struggling today. The web developers forgot to update Akebia's website. No one knows vadadustat was approved! https://akebia.com/research-and-development/ Just sent a quick Email to our beloved Ms. Carrasco so they can update that; just 4 months later...

vickonix Posted - 12 hours ago

$AKBA fuck!